Your Semaglutide Results Timeline: What to Expect Week by Week in 2026

Most people on semaglutide or tirzepatide notice less hunger within the first few weeks, but real movement on the scale builds over months. In trials, average weight loss reached about 15% for semaglutide at 68 weeks and up to roughly 22.5% for tirzepatide at 72 weeks. Your own pace depends on dose titration, starting weight, and daily habits. This guide maps the typical GLP-1 weight loss timeline week by week, so you know what's normal, and being proactive about your metabolic health is a smart step worth trusting.

When do GLP-1s start working?

Appetite usually eases in the first 1 to 4 weeks; steady weight loss takes months. Semaglutide and tirzepatide both start at a low dose and step up over roughly 16 weeks, so the biggest changes come as the dose climbs and your body reaches a stable blood level after about 4 to 5 weeks.

Think of it in two layers. The first is how you feel: quieter hunger and smaller portions, often within a few weeks. The second is the scale, which moves more slowly and more steadily once you reach your target dose. Both are covered below for compounded semaglutide and compounded tirzepatide.

What decides your timeline

Your timeline is shaped by a few things, not just the drug. The same dose can move two people at different speeds, and that is normal.

• Titration schedule: both drugs start low and step up every 4 weeks, so early weeks are about tolerance, not maximum effect.
• Which medication and dose: higher target doses produced larger average loss in trials.
• Starting weight: a higher starting point often means a larger absolute drop in the early months.
• Habits: protein intake, movement, and sleep affect how much of the change sticks.
• Individual response: some people are early responders, others take longer to reach the same point.

Weeks 1 to 4: the ramp-up

The first month is about starting low and letting your body adjust. Both semaglutide and tirzepatide begin at a starter dose, so early weight change is usually small even though appetite often shifts first.

Here is what is happening inside. GLP-1 medications act on receptors in the brain and gut that control hunger and fullness, which is why portions shrink and cravings quiet down before the scale moves much.

• Week 1: many people feel a subtle drop in hunger; some feel nothing yet.
• Weeks 2 to 3: reduced cravings and smaller portions become more common.
• Weeks 4 to 5: blood levels reach a steady state, so effects feel more consistent.
• Scale: often a few pounds, sometimes little change; this is expected on starter doses.

Semaglutide results, week by week

Semaglutide builds slowly and steadily. In the STEP 1 trial, adults on the 2.4 mg weekly dose lost an average of about 14.9% of body weight by week 68, versus 2.4% on placebo. Most of that came after the dose was fully stepped up.

Newer data pushed this further. In the 2025 STEP UP trial, a higher 7.2 mg dose produced about 20.7% average loss over 72 weeks. Longer STEP 5 data showed loss tends to plateau near week 60 and hold with continued use.

Tirzepatide results, week by week

Tirzepatide works on two receptors (GLP-1 and GIP) and, in trials, produced larger average loss. In SURMOUNT-1, adults reached about 15% (5 mg), 19.5% to 21.4% (10 mg), and up to 22.5% (15 mg) of body weight by week 72.

Slower responders are common and not a failure. In the post-hoc analysis, 90% of later responders still reached at least 5% loss by week 72, with a mean of about 24.8 weeks to hit their first 5%.

Deciding between the two? See semaglutide vs tirzepatide for a side-by-side.

Months 2 and 3: the build

This is when the scale usually catches up to the appetite changes. By months two and three, most people are at or near their target dose, and weekly loss tends to become more predictable.

• Appetite suppression is often at its most consistent between weeks 4 and 8.
• Weekly loss can range widely; a slow, steady drop beats a fast one for keeping muscle.
• Protein and resistance training matter now, since some lost weight is muscle. See protecting muscle on a GLP-1.
• Side effects like nausea usually settle as your body adapts.

If hunger feels too quiet or side effects linger, that is a dosing conversation, not a reason to quit. Some people do well on a gentler path, covered in GLP-1 microdosing.

When weight loss plateaus

Most people hit a plateau, and it does not mean the medication stopped working. Longer trials show weight loss tends to level off after roughly 60 weeks and then hold with continued use.

A plateau is often your body settling at a new set point. If it comes earlier than expected, small changes can help: revisit protein, movement, sleep, and dose fit with your physician. The full playbook is in breaking a GLP-1 plateau.

How side effects change over time

Most side effects are early and fade. Nausea, mild digestive upset, and fatigue are most common during titration and usually ease as your body adjusts and the dose stabilizes.

• Weeks 1 to 8: nausea and digestive changes are most likely, often mildest at lower doses.
• Each dose step-up can bring a short flare that typically settles within days.
• Steady state: many people report far fewer symptoms once at their target dose.
• Managing it: smaller meals, hydration, and slower titration help. See managing GLP-1 nausea.

For a fuller list specific to semaglutide, see semaglutide side effects. Anything severe or persistent is a reason to contact your prescriber.

How pru handles GLP-1 timelines

pru is a telehealth membership built around this exact timeline. You select the peptide you are interested in; a licensed physician confirms whether compounded semaglutide or tirzepatide is a fit, and an FDA-regulated 503A pharmacy fills it.

• Membership is about $50/month. See pricing for what is included.
• Peptides are billed at cost, itemized, with no member markup. A higher dose costs a little more but never carries a markup.
• Live weight-loss options: compounded semaglutide and compounded tirzepatide, the GLP-1 medicines studied above, prescribed by a physician and filled by a 503A pharmacy.
• Compounded medications are pharmacy-grade and prescription-only. They are not the branded products and are not FDA-approved drugs.

You may see retatrutide or cagrilintide mentioned as next-generation options with strong trial demand. They are investigational and not available as legitimate compounded products, so pru does not currently offer retatrutide or cagrilintide until there is a safe pathway for physician oversight and FDA-regulated 503A pharmacies. Be cautious of grey-market or research-grade vials sold without a prescription; those sit outside pharmacy oversight. If you are exploring them, read retatrutide vs tirzepatide, then talk to a physician about the compounded GLP-1s pru does offer.

Browse the full weight loss and metabolism lineup to compare. Getting ahead of your metabolic health is a smart, responsible choice, and pru exists to make that choice an accessible one: licensed physicians, pharmacy-grade medicine, and at-cost pricing. Take the next step when you are ready.

Related reading

Keep going with these guides:

• Semaglutide vs tirzepatide
• Breaking a GLP-1 weight loss plateau
• GLP-1 microdosing
• Protecting muscle on a GLP-1
• Managing GLP-1 nausea
• How to inject a GLP-1
• Compounded semaglutide product page

Common questions